Biologics

DRUG5 trials

Sponsors

Osaka University, Shinshu University, The University of Hong Kong-Shenzhen Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, Chao Ji

Conditions

Autoimmune diseasesCrohn DiseaseRheumatoid ArthritisSpondyloarthritis (SpA)Subclinical Psoriatic ArthritisUlcerative Colitis

Phase 2

Examination of Efficacy and Safety of Baricitinib in RA Patients

Shinshu UniversityRheumatoid Arthritis

Start: 2018-11-21End: 2025-11-20Target: 90Updated: 2021-09-21

Phase 4

Analysis of immune status in autoimmune diseases treated with Biologics

Active, not recruitingJPRN-UMIN000012916

Osaka UniversityAutoimmune diseases

Start: 2014-01-15Target: 20Updated: 2026-06-29

Unknown Phase

A Clinical Study to Evaluate the Efficacy of Biologics in SpA

The University of Hong Kong-Shenzhen HospitalSpondyloarthritis (SpA)

Start: 2022-01-12End: 2022-12-31Target: 40Updated: 2022-06-02

Multi-omics to Predict Responses to Biologics in IBD

Sixth Affiliated Hospital, Sun Yat-sen UniversityCrohn Disease, Ulcerative Colitis

Start: 2020-01-01End: 2024-11-01Target: 1050Updated: 2022-09-15

A Real-World Study of Biologic Therapy for Subclinical Psoriatic Arthritis

Enrolling by invitationNCT06686082

Chao JiSubclinical Psoriatic Arthritis

Start: 2023-11-01End: 2025-03-25Target: 150Updated: 2025-03-25

Related Papers

Intestinal mRNA expression profiles associated with mucosal healing in ustekinumab-treated Crohn's disease patients: bioinformatics analysis and prospective cohort validation

Journal of Translational Medicine2024-06-262 citations